Harrow, Inc. (HROW) stock
HROWNasdaqPharmaceutical PreparationsFiscal year ends December 31
$30.12+1.82 (+6.43%)
Close on Nov 13, 2026Market cap $1.13BP/E –Yield –
Harrow r&d expenses
Research and development expenses are spending on new products and technology.
Harrow's R&D Expenses for the twelve months ending Sep 30, 2026 was $35.98M, up 157.5% year over year. For fiscal 2025 it was $20.94M, up 71.2% from the year before. Over ten years it grew 51.4% a year on average. The highest annual figure on record is $20.94M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.94M | +71.2% |
| FY2024 | Dec 31, 2024 | $12.23M | +83.9% |
| FY2023 | Dec 31, 2023 | $6.65M | +118.1% |
| FY2022 | Dec 31, 2022 | $3.05M | -72.5% |
| FY2021 | Dec 31, 2021 | $11.08M | +359.3% |
| FY2020 | Dec 31, 2020 | $2.41M | +15.8% |
| FY2019 | Dec 31, 2019 | $2.08M | +152.5% |
| FY2018 | Dec 31, 2018 | $825.00K | +99.8% |
| FY2017 | Dec 31, 2017 | $413.00K | -44.1% |
| FY2016 | Dec 31, 2016 | $739.00K | +122.6% |
| FY2015 | Dec 31, 2015 | $332.00K | +40.1% |
| FY2014 | Dec 31, 2014 | $237.00K | -85.3% |
| FY2013 | Dec 31, 2013 | $1.62M | +24.5% |
| FY2012 | Dec 31, 2012 | $1.30M | +1064.0% |
| FY2011 | Dec 31, 2011 | $111.55K | -42.7% |
| FY2010 | Dec 31, 2010 | $194.59K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $10.29M | +209.6% |
| Q2 FY2026 | Jun 30, 2026 | $8.07M | +181.5% |
| Q1 FY2026 | Mar 31, 2026 | $5.90M | +94.8% |
| Q4 FY2025 | Dec 31, 2025 | $11.72M | +146.5% |
| Q3 FY2025 | Sep 30, 2025 | $3.32M | +46.2% |
| Q2 FY2025 | Jun 30, 2025 | $2.87M | -6.1% |
| Q1 FY2025 | Mar 31, 2025 | $3.03M | +40.8% |
| Q4 FY2024 | Dec 31, 2024 | $4.76M | +42.5% |
| Q3 FY2024 | Sep 30, 2024 | $2.27M | +60.0% |
| Q2 FY2024 | Jun 30, 2024 | $3.05M | +163.0% |
| Q1 FY2024 | Mar 31, 2024 | $2.15M | +192.8% |
| Q4 FY2023 | Dec 31, 2023 | $3.34M | +374.5% |
| Q3 FY2023 | Sep 30, 2023 | $1.42M | +83.4% |
| Q2 FY2023 | Jun 30, 2023 | $1.16M | +27.0% |
| Q1 FY2023 | Mar 31, 2023 | $734.00K | +11.6% |
| Q4 FY2022 | Dec 31, 2022 | $703.00K | -82.2% |
| Q3 FY2022 | Sep 30, 2022 | $775.00K | -87.3% |
| Q2 FY2022 | Jun 30, 2022 | $914.00K | +115.1% |
| Q1 FY2022 | Mar 31, 2022 | $658.00K | +11.1% |
| Q4 FY2021 | Dec 31, 2021 | $3.94M | +567.0% |
| Q3 FY2021 | Sep 30, 2021 | $6.13M | +814.2% |
| Q2 FY2021 | Jun 30, 2021 | $425.00K | -43.3% |
| Q1 FY2021 | Mar 31, 2021 | $592.00K | +46.9% |
| Q4 FY2020 | Dec 31, 2020 | $591.00K | +39.4% |
| Q3 FY2020 | Sep 30, 2020 | $670.00K | +50.9% |
| Q2 FY2020 | Jun 30, 2020 | $749.00K | -7.5% |
| Q1 FY2020 | Mar 31, 2020 | $403.00K | -0.5% |
| Q4 FY2019 | Dec 31, 2019 | $424.00K | -2.1% |
| Q3 FY2019 | Sep 30, 2019 | $444.00K | +90.6% |
| Q2 FY2019 | Jun 30, 2019 | $810.00K | +1025.0% |
| Q1 FY2019 | Mar 31, 2019 | $405.00K | +365.5% |
| Q4 FY2018 | Dec 31, 2018 | $433.00K | +386.5% |
| Q3 FY2018 | Sep 30, 2018 | $233.00K | +269.8% |
| Q2 FY2018 | Jun 30, 2018 | $72.00K | -28.7% |
| Q1 FY2018 | Mar 31, 2018 | $87.00K | -45.6% |
| Q4 FY2017 | Dec 31, 2017 | $89.00K | -85.2% |
| Q3 FY2017 | Sep 30, 2017 | $63.00K | – |
| Q2 FY2017 | Jun 30, 2017 | $101.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $160.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $601.00K | – |
See a number that looks wrong?